TY - JOUR
T1 - In vivo quantification of mouse autoimmune arthritis by PET/CT
AU - Kundu-Raychaudhuri, Smriti
AU - Mitra, Anupam
AU - Datta-Mitra, Ananya
AU - Chaudhari, Abhijit
AU - Raychaudhuri, Siba P
PY - 2014
Y1 - 2014
N2 - Aim: To quantify the progression and severity of mouse collagen-induced arthritis (CIA) using an in vivo imaging tool, 18F-fluorodeoxyglucose (18F-FDG) PET/CT and validate it against gold standard 'histopathological' evaluation. Method: The PET radiotracer 18F-FDG, a marker for glucose metabolism, was injected in mice at different stages of CIA and the radiotracer distribution was imaged using a PET scanner. A sequential CT scan provided correlated anatomy. Radiotracer concentration was derived from PET/CT images for individual limb joints and on a per-limb basis at different stages of the disease. The imaging outcomes were subjected to correlation analysis with concurrently measured clinical and histological score. Results: Clinical and histological score, and hence disease severity, showed a strong linear correlation (r2 = 0.71, P = 0.001 and r2 = 0.87, P < 0.001, respectively) with radiotracer concentration measured from PET/CT during the progression of CIA. Conclusions: The strong positive correlation of the 18F-FDG PET/CT findings with the histopathological evaluation at different stages of the disease suggest the potential of this imaging tool for the non-invasive assessment of progression and severity in mouse autoimmune arthritis. Thus, in preclinical studies, 18F-FDG PET/CT can be considered as a non-invasive tool to develop novel therapies of inflammatory arthritis.
AB - Aim: To quantify the progression and severity of mouse collagen-induced arthritis (CIA) using an in vivo imaging tool, 18F-fluorodeoxyglucose (18F-FDG) PET/CT and validate it against gold standard 'histopathological' evaluation. Method: The PET radiotracer 18F-FDG, a marker for glucose metabolism, was injected in mice at different stages of CIA and the radiotracer distribution was imaged using a PET scanner. A sequential CT scan provided correlated anatomy. Radiotracer concentration was derived from PET/CT images for individual limb joints and on a per-limb basis at different stages of the disease. The imaging outcomes were subjected to correlation analysis with concurrently measured clinical and histological score. Results: Clinical and histological score, and hence disease severity, showed a strong linear correlation (r2 = 0.71, P = 0.001 and r2 = 0.87, P < 0.001, respectively) with radiotracer concentration measured from PET/CT during the progression of CIA. Conclusions: The strong positive correlation of the 18F-FDG PET/CT findings with the histopathological evaluation at different stages of the disease suggest the potential of this imaging tool for the non-invasive assessment of progression and severity in mouse autoimmune arthritis. Thus, in preclinical studies, 18F-FDG PET/CT can be considered as a non-invasive tool to develop novel therapies of inflammatory arthritis.
KW - in vivo imaging
KW - Inflammation
KW - Mouse CIA
KW - PET/CT
KW - Quantification
UR - http://www.scopus.com/inward/record.url?scp=84902931047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902931047&partnerID=8YFLogxK
U2 - 10.1111/1756-185X.12410
DO - 10.1111/1756-185X.12410
M3 - Article
C2 - 24965561
AN - SCOPUS:84902931047
JO - International Journal of Rheumatic Diseases
JF - International Journal of Rheumatic Diseases
SN - 1756-1841
ER -